Susquehanna International Group, LLP Ocuphire Pharma, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$2.59 - $3.64 $36,519 - $51,324	14,100 New	14,100 $42,000
Q2 2023 Aug 11, 2023	BUY	$3.63 - $6.38 $546,678 - $960,828	150,600 New	150,600 $653,000
Q3 2022 Nov 14, 2022	SELL	$1.82 - $2.79 $22,750 - $34,875	-12,500 Reduced 5.64%	209,000 $420,000
Q2 2022 Aug 15, 2022	BUY	$1.8 - $3.25 $375,300 - $677,625	208,500 Added 1603.85%	221,500 $425,000
Q1 2022 May 16, 2022	SELL	$2.75 - $4.39 $221,375 - $353,395	-80,500 Reduced 86.1%	13,000 $42,000
Q4 2021 Feb 14, 2022	BUY	$3.4 - $5.19 $124,100 - $189,435	36,500 Added 64.04%	93,500 $349,000
Q3 2021 Nov 15, 2021	BUY	$3.84 - $5.38 $218,880 - $306,660	57,000 New	57,000 $294,000

2.58M

14.1K

800

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $20.2M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.